We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

195 hedge funds and large institutions have $1.7B invested in Enanta Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 59 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 15

43% more capital invested

Capital invested by funds: $1.19B → $1.7B (+$508M)

24% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 59

7% more funds holding

Funds holding: 183 → 195 (+12)

4.86% more ownership

Funds ownership: 86.75% → 91.61% (+4.9%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

32% less call options, than puts

Call options by funds: $5.14M | Put options by funds: $7.51M

Holders
195
Holders Change
+12
Holders Change %
+6.56%
% of All Funds
4.22%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
29
Increased
73
Reduced
59
Closed
15
Calls
$5.14M
Puts
$7.51M
Net Calls
-$2.38M
Net Calls Change
-$2.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$26.5M
2
Ameriprise
Ameriprise
Minnesota
+$23.1M
3
Citadel Advisors
Citadel Advisors
Florida
+$21.5M
4
O
OrbiMed
New York
+$20.9M
5
MWNA
Marshall Wace North America
New York
+$18.6M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$13.6M
2
AC
Armistice Capital
New York
-$11.5M
3
Morgan Stanley
Morgan Stanley
New York
-$10.3M
4
GPP
Great Point Partners
Connecticut
-$10.2M
5
Goldman Sachs
Goldman Sachs
New York
-$6.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
151
Advantage Investment Management
Iowa
$138K – – –
FCM
152
Flinton Capital Management
Pennsylvania
$138K – – –
AIP
153
Ameritas Investment Partners
Nebraska
$133K – – –
CG
154
Cutler Group
California
$133K +$117K +1,300 +1,300%
MAM
155
Meeder Asset Management
Ohio
$117K -$48.2K -537 -31%
JG
156
Jefferies Group
New York
$107K +$100K +1,116 New
BWP
157
Baldwin Wealth Partners
Massachusetts
$96K – – –
SO
158
STRS Ohio
Ohio
$85K – – –
Parallax Volatility Advisers
159
Parallax Volatility Advisers
California
$80K +$74.9K +835 New
VFA
160
Valeo Financial Advisors
Indiana
$79K +$49.2K +549 +196%
SDIC
161
South Dakota Investment Council
South Dakota
$76K +$71.8K +800 New
Bank of Montreal
162
Bank of Montreal
Ontario, Canada
$74K -$8.88K -99 -11%
PNC Financial Services Group
163
PNC Financial Services Group
Pennsylvania
$71K +$9.69K +108 +17%
Zurich Cantonal Bank
164
Zurich Cantonal Bank
Switzerland
$68K +$2.87K +32 +5%
PM
165
Prosight Management
Texas
$68K +$63.6K +709 New
SGAM
166
Smith Group Asset Management
Texas
$50K -$117K -1,300 -71%
LIA
167
LS Investment Advisors
Michigan
$50K – – –
FGAM
168
Financial Gravity Asset Management
Texas
$49K +$46K +513 New
SWA
169
Sutton Wealth Advisors
Florida
$47K – – –
MOACM
170
Mutual of America Capital Management
New York
$43K +$5.38K +60 +15%
AG
171
Advisor Group
Arizona
$29K -$10.2K -114 -28%
Royal Bank of Canada
172
Royal Bank of Canada
Ontario, Canada
$28K – – –
RA
173
Royce & Associates
New York
$26K -$1.17K -13 -5%
GI
174
Gradient Investments
Minnesota
$26K – – –
PRC
175
Pearl River Capital
Michigan
$26K +$16K +178 +175%
5 6
7
8 9

ENTA Hedge Fund Activity: Q1 2019 in Review

195 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2019, worth a combined $1.7B — up 43% from $1.19B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ENTA positions and 15 closed out — a net gain of 14 holders — while 73 added to existing stakes and 59 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $26.5M. The largest seller was Renaissance Technologies, cutting an estimated $13.6M.

  • 195 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2019, up from 183 in Q4 2018.
  • Funds reported $1.7B of Enanta Pharmaceuticals stock for Q1 2019, up 43% quarter-over-quarter.
  • 29 funds opened new Enanta Pharmaceuticals positions in Q1 2019 and 15 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $26.5M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2019 was Renaissance Technologies, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2019.